Boan Biotech Presents Early Findings about BA1301 at ESMO 2025

Boan Biotech today announced that the preliminary results of the ongoing Phase I clinical study for its BA1301, an investigational antibody-drug conjugate (ADC), were recently presented at the 2025 Co...

Articles of Association

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

INTERIM REPORT 2025

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2025

Boan Biotech Announces 2025 Half-Year Results

Boan Biotech (6955.HK) today announced its 2025 half-year results and latest developments.During the reporting period, the company's total revenue was RMB 393 million, up 8% YoY, and the contribut...

ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2025

NOTICE OF BOARD MEETING

Next Day Disclosure Return

COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE